Antimicrobial Resistance Profiling of Routine Antibiotics and Mango Kernel (Mangifera Indica L.) Ethanolic Extract on Multidrug-Resistant Acinetobacter Isolates

Main Article Content

Ali Al Bshabshe et al.

Abstract

Multidrug-resistant (MDR) Acinetobacter species are opportunistic pathogens that are clinically important, which causes severe infection during a prolonged stay in an Intensive Care Unit (ICU) of the hospital. In the present study, we screened clinical isolates of Acinetobacter species for its MDR nature from the ICU of a tertiary care centre at Abha, Saudi Arabia during the period of 2013-2017. Confirmed MDR Acinetobacter species clinical isolates were challenged against ethanolic extracts from mango kernel (Mangifera indica L.) by classical disc diffusion method. In total, we characterized 124 MDR Acinetobacter isolates, out of which 62 (50%) were Acinetobacter baumannii (MDR-AB), 41 (33.1%) were Acinetobacter baumannii complex (MDR-ABC), 15 (12.1%) were Acinetobacter baumannii-haemolyticus (MDR-ABH), 3 (2.4%) were Acinetobacter haemolyticus  (MDR-AH) and 3 (2.4%) were Acinetobacter iwoffii (MDR-AI). We observed that MDR-AB isolates were inhibited by ethanolic extract of M. indica with minimum inhibition concentration (MIC) of 0.25 mg/ml. Concentrations of 50 mg/mL, 5 mg/mL and 0.5 mg/mL exhibited average inhibition zones of 18.74±0.09, 15.51±0.08 and 9.74±0.06 mm respectively showing a concentration dependent antagonisms (R2= 0.947). The results of M. indica were comparable to Colistin inhibition zone of 14.98±0.72 mm with 50 mg/mL and 5 mg/mL exceeded those of the positive control (p= 0.6721 and 0.1045, respectively). However, Colistin showed minor increase over M. indica at the concentration 0.5-mg/ mL (p= 0.5384). More specifically, MDR-AB strains have shown a substantial susceptibility to mango kernel extract (0.25 mg/mL) with antagonism similar to that of Colistin. Thus, the study shows that the extracts of mango kernel as a potential drug target and could be potentially used as an adjunct treatment along with the standard agents to treat Acinetobacter infections.

Article Details

Section
Articles